ADOPT: evidence for early use of thiazolidinediones

References

• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet365(9467), 1333–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Haring H, Fritsche A. For debate: Starling’s curve of the pancreas – overuse of a concept? Horm. Metab. Res.35(7), 391–395 (2003).
   Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia49(8), 1711–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA281(21), 2005–2012 (1999).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann. Med.34(3), 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in Type 2 diabetes. Annu. Rev. Med.57, 265–281 (2006).
   PubMed Web of Science ®Google Scholar
• Leiter LA. Can thiazolidinediones delay disease progression in Type 2 diabetes? Curr. Med. Res. Opin.22(6), 1193–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med.333(9), 550–554 (1995).
   PubMed Web of Science ®Google Scholar
• Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for Type 2 diabetes mellitus. Pharmacotherapy26(3), 360–374 (2006).
   PubMedGoogle Scholar
• Meier JJ, Nauck MA. Incretins and the development of Type 2 diabetes. Curr. Diab. Rep.6(3), 194–201 (2006).
   PubMedGoogle Scholar
• Mest HJ. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in Type 2 diabetics via incretin enhancement. Curr. Opin. Investig. Drugs7(4), 338–343 (2006).
   Google Scholar
• Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr. Med. Res. Opin.22(6), 1211–1215 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Marx N, Wohrle J, Nusser T et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation112(18), 2792–2798 (2005).
   PubMed Web of Science ®Google Scholar
• Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes Care29(1), 101–106 (2006).
   PubMed Web of Science ®Google Scholar
• Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset Type 2 diabetes. Diabetes Care29(5), 1039–1045 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care28(7), 1547–1554 (2005).
   PubMed Web of Science ®Google Scholar
• Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of Type 2 diabetes. Diabetologia48(12), 2477–2481 (2005).
   PubMed Web of Science ®Google Scholar
• Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in Type 2 diabetes. J. Clin. Endocrinol. Metab.89(12), 6048–6053 (2004).
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Rundek T, Nicasio J, Deshmukh M, Sowers JR. The DREAM trial and the prospect of diabetes prevention. Curr. Diab. Rep.6(3), 205–206 (2006).
   Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA287(3), 360–372 (2002).
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of Type 2 diabetes: impact on glucose tolerance and β-cell function. J. Clin. Endocrinol. Metab.89(6), 2846–2851 (2004).
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes51(9), 2796–2803 (2002).
   PubMed Web of Science ®Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med.22(4), 399–405 (2005).
   PubMed Web of Science ®Google Scholar
• Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of Type 2 diabetes. Diabetes Obes. Metab.8(1), 110–115 (2006).
   PubMed Web of Science ®Google Scholar
• Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with Type 2 diabetes. Diabetes Care27(11), 2585–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol. Drug Saf. (2006) (Epub ahead of print).
   Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care23(11), 1605–1611 (2000).
   PubMed Web of Science ®Google Scholar